

ENANTA PHARMACEUTICALS INC  
Form SC 13G/A  
February 13, 2014

**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**SCHEDULE 13G**

**Under the Securities Exchange Act of 1934**  
**(Amendment No. 1)\***

**ENANTA PHARMACEUTICALS, INC.**

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**29251M106**

(CUSIP Number)

**December 31, 2013**

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: ENANTA PHARMACEUTICALS INC - Form SC 13G/A

CUSIP No. 29251M 106

13G

- |     |   |  |
|-----|---|--|
| 1.  | Names of Reporting Persons<br>HBM Healthcare Investments (Cayman) Ltd.                                    |  |
| 2.  | Check the Appropriate Box if a Member of a Group (See Instructions)                                       |  |
|     | (a) <input type="radio"/>   |  |
|     | (b) <input type="radio"/>   |  |
| 3.  | SEC Use Only  |  |
| 4.  | Citizenship or Place of Organization<br>Cayman Islands, British West Indies                               |  |
| 5.  | Sole Voting Power<br>868,088  | Number of<br>Shares<br>Beneficially<br>Owned by<br>Each<br>Reporting<br>Person With: |
| 6.  | Shared Voting Power<br>0  |  |
| 7.  | Sole Dispositive Power<br>868,088   |  |
| 8.  | Shared Dispositive Power<br>0   |  |
| 9.  | Aggregate Amount Beneficially Owned by Each Reporting Person<br>868,088 (1)                               |  |
| 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) <input type="radio"/> |  |
| 11. | Percent of Class Represented by Amount in Row 9<br>4.83%(2)   |  |
| 12. | Type of Reporting Person (See Instructions)<br>CO   |  |

---

(1) Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman) Ltd. consists of Jean-Marc Lesieur, Sophia Harris, Richard Coles, Dr. Andreas Wicki and John Urquhart, none of whom has individual voting or investment power with respect to the shares.

(2) This percentage is calculated based upon 17,961,713 shares of the Issuer's Common Stock outstanding as of December 16, 2013, as set forth in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2013.

- Item 1(a).** Name of Issuer:  
Enanta Pharmaceuticals, Inc.
- Item 1(b).** Address of Issuer's Principal Executive Offices:  
500 Arsenal Street  
Watertown, Massachusetts 02472
- Item 2(a).** Name of Person Filing:  
HBM Healthcare Investments (Cayman) Ltd.
- Item 2(b).** Address of Principal Business Office or, if none, Residence:  
Governors Square, Suite #4-212-2  
23 Lime Tree Bay Ave.  
West Bay  
Grand Cayman, Cayman Islands
- Item 2(c).** Citizenship:  
Cayman Islands, British West Indies
- Item 2(d).** Title of Class of Securities:  
Common Stock
- Item 2(e).** CUSIP Number:  
29251M106
- Item 3.** **If this statement is filed pursuant to §§240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:**  
Not applicable

**Item 4. Ownership**

- |     |  |  |
|-----|--|--|
| (a) | Amount beneficially owned:                   |  |
|     |  | 868,088 (1)  |
| (b) | Percent of class:                            |  |
|     |  | 4.83%(2)   |
| (c) | Number of shares as to which the person has: |  |
|     | (i)  | Sole power to vote or to direct the vote:                |
|     |  | 868,088 (1)  |
|     | (ii)   | Shared power to vote or to direct the vote:              |
|     |  | 0  |
|     | (iii)  | Sole power to dispose or to direct the disposition of:   |
|     |  | 868,088 (1)  |
|     | (iv)   | Shared power to dispose or to direct the disposition of: |
|     |  | 0  |

**Item 5. Ownership of 5 Percent or Less of a Class**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following .

**Item 6. Ownership of More than 5 Percent on Behalf of Another Person**

Not applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not applicable

**Item 8. Identification and Classification of Members of the Group**

Not applicable

**Item 9. Notice of Dissolution of a Group**

Not applicable

**Item 10. Certification**

Not applicable

(1) Voting and investment power over the shares held by HBM Healthcare Investments (Cayman) Ltd. is exercised by the board of directors of HBM Healthcare Investments (Cayman) Ltd. The board of directors of HBM Healthcare Investments (Cayman) Ltd. consists of Jean-Marc Lesieur, Sophia Harris, Richard Coles, Dr. Andreas Wicki and John Urquhart, none of whom has individual voting or investment power with respect to the shares.

(2) This percentage is calculated based upon 17,961,713 shares of the Issuer's Common Stock outstanding as of December 16, 2013, as set forth in the Issuer's Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 18, 2013.



**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 11, 2014

**HBM HEALTHCARE INVESTMENTS (CAYMAN) LTD.**

By: /s/ Jean-Marc Lesieur  
Jean-Marc Lesieur  
Director

**Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)**